Thomas Kosten

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Buprenorphine for office-based practice: consensus conference overview
    Thomas R Kosten
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA
    Am J Addict 13:S1-7. 2004
  2. ncbi Management of drug and alcohol withdrawal
    Thomas R Kosten
    Departments of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    N Engl J Med 348:1786-95. 2003
  3. ncbi Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, VA New England MIRECC, West Haven, CT 06516, USA
    Addiction 98:665-71. 2003
  4. ncbi Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, VA New England MIRECC, VA Caonnecticut Healthcare System, 950 Campbell Avenue, Bldg 35, West Haven, CT 06516, USA
    Drug Alcohol Depend 70:315-25. 2003
  5. ncbi Therapeutic vaccines for substance dependence
    Thomas R Kosten
    Yale University School of Medicine, Department of Psychiatry, West Haven, Connecticut 06516, USA
    Expert Rev Vaccines 1:363-71. 2002
  6. ncbi Aspirin or amiloride for cerebral perfusion defects in cocaine dependence
    Thomas R Kosten
    Department of Psychiatry, 151D, Yale University School of Medicine, VA Connecticut Healthcare System, 950 Campbell Avenue Bldg, Room 41, West Haven, CT 06516, USA
    Drug Alcohol Depend 71:187-94. 2003
  7. ncbi The neurobiology of opioid dependence: implications for treatment
    Thomas R Kosten
    Yale University School of Medicine, New Haven, Connecticut, USA
    Sci Pract Perspect 1:13-20. 2002
  8. ncbi Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Addict 13:191-201. 2004
  9. ncbi New medication strategies for comorbid substance use and bipolar affective disorders
    Thomas R Kosten
    Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Biol Psychiatry 56:771-7. 2004
  10. ncbi Immunotherapy for the treatment of drug abuse
    Thomas Kosten
    Yale School of Medicine, Department of Psychiatry, West Haven, CT 06516, USA
    Pharmacol Ther 108:76-85. 2005

Research Grants

  1. Pharmacotherapy for opioid and cocaine dependence
    Bruce Rounsaville; Fiscal Year: 2005

Detail Information

Publications76

  1. ncbi Buprenorphine for office-based practice: consensus conference overview
    Thomas R Kosten
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA
    Am J Addict 13:S1-7. 2004
    ..This opportunity has a three-year window, however, and a critical need will be to attract a sufficient number of physicians into prescribing buprenorphine/naloxone in order to allow our patients increased access to this treatment...
  2. ncbi Management of drug and alcohol withdrawal
    Thomas R Kosten
    Departments of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    N Engl J Med 348:1786-95. 2003
  3. ncbi Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, VA New England MIRECC, West Haven, CT 06516, USA
    Addiction 98:665-71. 2003
    ..The 'escalating CM' was eliminated during months 4-6 to assess any reduction in drug-free urines...
  4. ncbi Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, VA New England MIRECC, VA Caonnecticut Healthcare System, 950 Campbell Avenue, Bldg 35, West Haven, CT 06516, USA
    Drug Alcohol Depend 70:315-25. 2003
    ..DMI and CM had independent and additive effects in facilitating cocaine-free urines in buprenorphine maintained patients. The antidepressant appeared to enhance responsiveness to CM reinforcement...
  5. ncbi Therapeutic vaccines for substance dependence
    Thomas R Kosten
    Yale University School of Medicine, Department of Psychiatry, West Haven, Connecticut 06516, USA
    Expert Rev Vaccines 1:363-71. 2002
    ..Other immunotherapy may include treatment of drug overdose, prevention of brain or cardiac toxicity and protection of a fetus during pregnancy in a drug abuser...
  6. ncbi Aspirin or amiloride for cerebral perfusion defects in cocaine dependence
    Thomas R Kosten
    Department of Psychiatry, 151D, Yale University School of Medicine, VA Connecticut Healthcare System, 950 Campbell Avenue Bldg, Room 41, West Haven, CT 06516, USA
    Drug Alcohol Depend 71:187-94. 2003
    ..Platelet aggregation after ADP showed no significant change during the month, but reduced rCBF significantly improved after 1-month treatment with amiloride compared with placebo and cocaine abstinence alone...
  7. ncbi The neurobiology of opioid dependence: implications for treatment
    Thomas R Kosten
    Yale University School of Medicine, New Haven, Connecticut, USA
    Sci Pract Perspect 1:13-20. 2002
    ..Despite the effectiveness of medications, they must be used in conjunction with appropriate psychosocial treatments...
  8. ncbi Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Addict 13:191-201. 2004
    ..Cocaine-free urines showed no association with depression. This poor outcome with desipramine and buprenorphine suggests that this medication combination is not indicated in depressed opioid-dependent patients...
  9. ncbi New medication strategies for comorbid substance use and bipolar affective disorders
    Thomas R Kosten
    Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Biol Psychiatry 56:771-7. 2004
    ..Pemoline might be the best option for minimizing the risk of SUD complicating comorbid ADHD with BPD...
  10. ncbi Immunotherapy for the treatment of drug abuse
    Thomas Kosten
    Yale School of Medicine, Department of Psychiatry, West Haven, CT 06516, USA
    Pharmacol Ther 108:76-85. 2005
    ..Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions...
  11. ncbi Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response
    Thomas Kosten
    Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Am J Addict 14:8-17. 2005
    ..The CU+ patients showed a treatment effect of DMI. This DMI effect was significant in patients maintained on BUP but not on Meth...
  12. ncbi Ketoconazole increases cocaine and opioid use in methadone maintained patients
    Thomas R Kosten
    Department of Psychiatry 151D, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Drug Alcohol Depend 66:173-80. 2002
    ..Thus, in agreement with the negative results from acute dosing studies in primates and humans, chronic ketoconazole treatment does not appear to reduce cocaine or opioid use in humans maintained on methadone...
  13. ncbi The Lexington narcotic farm
    Thomas R Kosten
    Department of Psychiatry, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Am J Psychiatry 159:22. 2002
  14. ncbi Human therapeutic cocaine vaccine: safety and immunogenicity
    Thomas R Kosten
    Department of Psychiatry, School of Medicine, Yale University, 950 Campbell Avenue, West Haven, CT 06516, USA
    Vaccine 20:1196-204. 2002
    ..Thus, the therapeutic vaccine was well tolerated with dose related increases in antibody levels, and a high proportion of patients recruited into the study were retained...
  15. ncbi Cue-induced brain activity changes and relapse in cocaine-dependent patients
    Thomas R Kosten
    Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Neuropsychopharmacology 31:644-50. 2006
    ..This physiological activation was a better predictor of relapse than subjective reports of craving, and may be a useful target for treatment development...
  16. ncbi The potential of dopamine agonists in drug addiction
    Thomas R Kosten
    Yale University School of Medicine, VA Connecticut Healthcare System, Department of Psychiatry, West Haven, CT 06516, USA
    Expert Opin Investig Drugs 11:491-9. 2002
    ..Animal studies also suggest that tailoring treatment to subgroups of patients based on genotype may improve responses...
  17. ncbi Preliminary study of buprenorphine and bupropion for opioid-dependent smokers
    Marc E Mooney
    Department of Psychiatry, Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55414, USA
    Am J Addict 17:287-92. 2008
    ..These preliminary findings do not support the efficacy of BUPRO, in combination with BUPRE, for the concurrent treatment of opioid and tobacco addiction...
  18. ncbi Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers
    Mehmet Sofuoglu
    Department of Psychiatry, VA Connecticut Healthcare System, School of Medicine, Yale University, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, USA
    Psychopharmacology (Berl) 184:645-51. 2006
    ..While a recent clinical study has demonstrated the potential utility of topiramate for smoking cessation in alcohol-dependent smokers, the effects of topiramate on tobacco addiction have not been systematically examined in humans...
  19. ncbi Disulfiram enhances subjective effects of dextroamphetamine in humans
    Mehmet Sofuoglu
    Yale University, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, United States
    Pharmacol Biochem Behav 90:394-8. 2008
    ..How these enhanced subjective amphetamine responses affect cocaine use behavior remains to be determined in future clinical trials...
  20. ncbi Atomoxetine attenuates dextroamphetamine effects in humans
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Am J Drug Alcohol Abuse 35:412-6. 2009
    ..Although preclinical studies support the contribution of the noradrenergic system activation in mediating the acute effects of amphetamines, these findings have not been followed up in clinical studies...
  21. ncbi Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers
    Mehmet Sofuoglu
    Department of Psychiatry and Veterans Administration Connecticut Healthcare System, School of Medicine, Yale University, West Haven, CT 06515, USA
    Behav Pharmacol 17:731-5. 2006
    ..Attenuation of the rating of 'bad effects' by carvedilol suggests that noradrenergic activation may also mediate the aversive effects of nicotine...
  22. ncbi Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans
    Mehmet Sofuoglu
    Department of Psychiatry and VA Connecticut Healthcare System, School of Medicine, Yale University, 950 Campbell Avenue, West Haven, CT 06516, USA
    Psychopharmacology (Berl) 213:61-8. 2011
    ..The goal of this study was to determine minocycline's effects on the acute physiological, behavioral, and subjective responses to dextroamphetamine (DAMP) in healthy volunteers...
  23. ncbi Cocaine withdrawal symptoms predict medication response in cocaine users
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Am J Drug Alcohol Abuse 32:617-27. 2006
    ..This hypothesis needs to be tested in prospective clinical trials...
  24. ncbi Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice
    Stacey C Sigmon
    Department of Psychiatry, University of Vermont College of Medicine, Burlington, 05401, USA
    Am J Drug Alcohol Abuse 38:187-99. 2012
    ..e., methadone, buprenorphine) often produces favorable outcomes, detoxification followed by treatment with the μ-opioid receptor antagonist naltrexone may offer a potentially useful alternative to agonist maintenance for some patients...
  25. ncbi Riluzole and D-amphetamine interactions in humans
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, United States
    Prog Neuropsychopharmacol Biol Psychiatry 32:16-22. 2008
    ..The mechanism accounting for these findings is unclear, but may involve processes other than decreased glutamate release by riluzole. The effects of glutamate medications on psychostimulant responses need to be further examined...
  26. ncbi Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers
    Mehmet Sofuoglu
    Department of Psychiatry, VA Connecticut Healthcare System, Yale University, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, USA
    Psychopharmacology (Berl) 181:504-10. 2005
    ..These preclinical studies have not been followed up in systematic human studies...
  27. ncbi Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action
    Dennis S Charney
    Department of Psychiatry, University of Pennsylvania School of Medicine, 3900 Chestnut Street, Philadelphia, PA 19104-6178, USA
    Biol Psychiatry 56:703-13. 2004
  28. ncbi Dopamine and serotonin transporter availability in chronic heroin users: a [¹²³I]β-CIT SPECT imaging study
    Kelly P Cosgrove
    Yale University School of Medicine and the VACHS, New Haven, CT 06516, United States
    Psychiatry Res 184:192-5. 2010
    ..Heroin users had statistically similar striatal DA and brainstem and diencephalon 5-HT transporter availability compared with controls. No associations between transporter availability and heroin use characteristics were found...
  29. ncbi Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research
    Rungnapa Hirunsatit
    Yale University School of Medicine, Department of Psychiatry, New Haven, CT, USA
    BMC Genet 8:71. 2007
    ....
  30. ncbi Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data
    Nashaat N Boutros
    VA-Connecticut Healthcare System West Haven Campus, Yale University School of Medicine, 950 Campbell Avenue (116A, West Haven, CT 06516, USA
    Biol Psychiatry 51:683-6. 2002
    ..Further exploration of these factors seems warranted...
  31. ncbi Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population
    James Poling
    Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven 06516, USA
    Arch Gen Psychiatry 63:219-28. 2006
    ..No effective pharmacotherapies exist for cocaine dependence, although contingency management (CM) has demonstrated efficacy...
  32. ncbi Tiagabine affects the subjective responses to cocaine in humans
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, West Haven, CT, USA
    Pharmacol Biochem Behav 82:569-73. 2005
    ..GABA medications, including tiagabine, are currently being evaluated in controlled clinical trials for the treatment of cocaine dependence...
  33. ncbi Treatment outcome predictors for cocaine dependence
    James Poling
    Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System West Haven, CT 06516, USA
    Am J Drug Alcohol Abuse 33:191-206. 2007
    ..Initial promising findings with genetic polymorphism, brain activation, and stress response have also been found and need to be replicated in future studies...
  34. ncbi Pharmacogenetic treatments for drug addiction: alcohol and opiates
    Colin N Haile
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Drug Alcohol Abuse 34:355-81. 2008
    ..This review aims to cover these developments in the pharmacotherapy of alcohol and opiates, two addictive drugs for which we have the majority of our FDA approved pharmacotherapies...
  35. ncbi Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study
    Mehmet Sofuoglu
    Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, Connecticut, USA
    Exp Clin Psychopharmacol 15:453-60. 2007
    ..60 vs. 0.73; U=4837, p<.04). These preliminary findings do not support the efficacy of progesterone in male cocaine users. The efficacy of progesterone in female cocaine users remains to be determined in future studies...
  36. ncbi Vaccine pharmacotherapy for the treatment of cocaine dependence
    Bridget A Martell
    Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 58:158-64. 2005
    ..Cocaine abuse has no established pharmacotherapy, but active immunotherapy with a cocaine vaccine shows promise as a therapeutic intervention...
  37. ncbi Cerebral perfusion defects in combined cocaine and alcohol dependence
    P C Gottschalk
    Departments of Veterans and Psychiatry 116A, Yale University School of Medicine, VA Connecticut Healthcare System, Psychiatry 151D, 950 Campbell Avenue, Building 35, Room 41, West Haven, CT 06516, USA
    Drug Alcohol Depend 68:95-104. 2002
    ....
  38. ncbi Pharmacotherapeutic environments for substance use disorders
    Tracie J Gardner
    Am J Drug Alcohol Abuse 33:627-9. 2007
  39. ncbi Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia
    Xiang Yang Zhang
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 2002 Holcombe Boulevard, Houston, TX 77030, USA
    Neuropsychopharmacology 32:2020-4. 2007
    ....
  40. ncbi Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery
    Anthony E Brown
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas 77098, USA
    Am J Drug Alcohol Abuse 33:611-7. 2007
    ..These findings encourage a controlled trial to determine if this work has efficacy for practitioners in substance abuse treatment...
  41. ncbi Treatment of patients with substance use disorders, second edition. American Psychiatric Association
    Herbert D Kleber
    Am J Psychiatry 164:5-123. 2007
  42. ncbi Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings
    Rajita Sinha
    Department of Psychiatry, Yale University School of Medicine, 34 Park Street, Room S110, New Haven, CT 06519, USA
    Psychopharmacology (Berl) 190:569-74. 2007
    ..A preliminary study examined whether lofexidine decreases stress-induced and cue-induced opioid craving and improves opioid abstinence in naltrexone-treated opioid-dependent individuals...
  43. ncbi Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients
    James Poling
    Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Am J Addict 16:187-94. 2007
    ..The results indicate that neither citalopram nor citalopram augmented with bupropion were more effective than placebo in the treatment of opioid abuse...
  44. ncbi Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients
    Gerardo Gonzalez
    Department of Psychiatry, Yale University, New Haven, CT 06511, USA
    Drug Alcohol Depend 87:1-9. 2007
    ..GABAergic medications appear to reduce the reinforcing effects of cocaine by attenuating cocaine-induced dopamine release. This study evaluated gabapentin and tiagabine compared to placebo in reducing cocaine taking behavior...
  45. ncbi Emerging pharmacological strategies in the fight against cocaine addiction
    Mehmet Sofuoglu
    Department of Psychiatry, VA Connecticut Healthcare System, Yale University, School of Medicine, West Haven, CT 06516, USA
    Expert Opin Emerg Drugs 11:91-8. 2006
    ..Last, a cocaine vaccine that slows entry of cocaine into the brain holds promise. These promising findings need to be further tested in controlled clinical trials...
  46. ncbi Antisocial personality and stress-induced brain activation in cocaine-dependent patients
    Chiang Shan R Li
    Department of Psychiatry, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Neuroreport 17:243-7. 2006
    ..These results highlight important sex differences in the association between antisocial personality and distress processing in cocaine-dependent individuals...
  47. ncbi Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study
    Rajita Sinha
    Department of Psychiatry, Yale University School of Medicine, 34 Park Street, Room S110, New Haven, CT 06519, USA
    Psychopharmacology (Berl) 183:171-80. 2005
    ..Identifying neural activity associated with stress and stress-induced cocaine craving is important in understanding the neurobiology of cocaine craving and relapse...
  48. ncbi The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects
    Danielle Abi-Saab
    Yale University School of Medicine, VA Connecticut Healthcare System, Department of Psychiatry, West Haven, Connecticut 06516, USA
    Am J Addict 14:166-78. 2005
    ..The vasodilatation produced by alcohol may attenuate some of the vasoconstriction and neurotoxic effects of cocaine, accounting for the fewer deficits in this group...
  49. ncbi Therapeutic vaccines for substance dependence
    Margaret Haney
    College of Physicians and Surgeons of Columbia University and the New York State Psychiatric Institute, Department of Psychiatry, New York, NY 10032, USA
    Expert Rev Vaccines 3:11-8. 2004
    ..Overall, immunotherapy offers a range of potential treatment options: drug treatment, as well as the treatment of overdose, prevention of brain or cardiac toxicity and fetal protection in pregnant drug abusers...
  50. ncbi Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence
    Mehmet Sofuoglu
    Department of Psychiatry and VA Connecticut Healthcare System, School of Medicine, Yale University, West Haven, Connecticut 06516, USA
    Am J Drug Alcohol Abuse 29:713-27. 2003
    ..These results suggest that baseline cocaine urine results should be considered as stratifying variables in clinical trials for cocaine dependence...
  51. ncbi Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study
    Gerardo Gonzalez
    Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA
    Addiction 98:1625-32. 2003
    ..We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients...
  52. ncbi Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats
    Colin N Haile
    Department of Neurosurgery, Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Biol Psychiatry 54:915-21. 2003
    ..CONCLUSIONS: Because DS shows treatment efficacy for cocaine addiction, results from this study suggest potential treatment agents should enhance, not attenuate, locomotor sensitization in rats...
  53. ncbi Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management
    Gerardo Gonzalez
    Department of Psychiatry, Yale University School of Medicine, and VA Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Am J Drug Alcohol Abuse 29:497-514. 2003
    ..The ND cocaine-abusing, opiate-dependent patients may be more responsive to the anticraving effects of DMI...
  54. ncbi Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans
    Mehmet Sofuoglu
    Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA
    Pharmacol Biochem Behav 75:801-8. 2003
    ..These results suggest that isradipine alone or in combination with naltrexone attenuates some of the physiological effects of cocaine...
  55. ncbi D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure
    Alison Oliveto
    Department of Psychiatry, Yale School of Medicine and Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Exp Clin Psychopharmacol 11:237-46. 2003
    ..Naloxone attenuated D-cycloserine-induced increases in systolic blood pressure. These results suggest that D-cycloserine at doses up to 500 mg/70 kg may have some limited usefulness in relieving symptoms of opioid withdrawal...
  56. ncbi Coordination of medical care and opioid dependence treatment in primary care: a case report
    David A Fiellin
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
    Subst Abus 24:43-6. 2003
  57. ncbi Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits
    P C H Gottschalk
    Department of Psychiatry, Yale University School of Medicine and the VA Connecticut Healthcare System, West Haven, Conn 06516, USA
    Am J Addict 11:200-8. 2002
    ..These deficits may represent segmental cerebral vasospasm that was reversed by this vasodilating agent in cocaine abusers with areas of hypo-perfusion (deficits) as baseline...
  58. ncbi A placebo controlled trial of bupropion for smoking cessation in schizophrenia
    Tony P George
    Program for Research in Smokers with Mental Illness and Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 52:53-61. 2002
    ....
  59. ncbi Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers
    Alan Feingold
    Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven 06516, USA
    Am J Addict 11:111-23. 2002
    ....
  60. ncbi Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients
    Susan M Stine
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 2761 E. Jefferson Avenue, Detroit, MI 48207, USA
    Biol Psychiatry 51:642-51. 2002
    ..Medications that increase synaptic noradrenaline should be used with care in opioid-dependent patients...
  61. ncbi Gender-specific vulnerability for rCBF abnormalities among cocaine abusers
    Karen A Tucker
    Department of Psychiatry, VA Connecticut Healthcare System, Yale University School of Medicine, 950 Campbell Avenue, West Haven, CT 06516, USA
    Neuroreport 15:797-801. 2004
    ..The possibility of different neural mechanisms underlying relapse in men and women, and the implications for utilizing specialized treatments are discussed...
  62. ncbi Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers
    Jeffrey N Browndyke
    Department of Psychiatry and Human Behavior Brown Medical School, Providence, Rhode Island, USA
    J Neuroimaging 14:162-9. 2004
    ..While perfusion abnormalities have been shown to relate to cognitive deficits in this substance abuse population, the relationship between cognitive performance and the magnitude of perfusion abnormality has yet to be fully determined...
  63. ncbi Combating opiate dependence: a comparison among the available pharmacological options
    Gerardo Gonzalez
    Department of Psychiatry, Yale University School of Medicine, West Haven, CT 06516, USA
    Expert Opin Pharmacother 5:713-25. 2004
    ....
  64. ncbi Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients
    Alison Oliveto
    Department of Psychiatry, Yale School of Medicine and the VA CT Healthcare System, West Haven, CT, USA
    Drug Alcohol Depend 79:157-65. 2005
    ..These results suggest that an efficacious maintenance dose is necessary for contingencies to be effective in facilitating both opioid and cocaine abstinence...
  65. ncbi Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study
    Chiang Shan Ray Li
    Department of Psychiatry, Yale University, New Haven, Connecticut 06519, USA
    Biol Psychiatry 57:487-94. 2005
    ....
  66. ncbi Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings
    Nashaat N Boutros
    Department of Psychiatry, c o VA Connecticut Healthcare System, Yale University School of Medicine, 950 Campbell Avenue, 116A West Haven, CT 06516, USA
    J Psychiatr Res 39:295-302. 2005
    ..These data support our initial finding of decreased cortical excitability in abstinent cocaine-dependent subjects. We interpret this finding as a compensatory mechanism against the stimulating and epileptogenic effects of cocaine...
  67. ncbi Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence
    Richard S Schottenfeld
    Department of Psychiatry, Yale University School of Medicine, 34 Park St, Rm S204, New Haven, CT 06519, USA
    Am J Psychiatry 162:340-9. 2005
    ..This study compares effects of buprenorphine and methadone and evaluates the efficacy of combining contingency management with maintenance treatment for patients with co-occurring cocaine and opioid dependence...
  68. ncbi Novel approaches to the treatment of cocaine addiction
    Mehmet Sofuoglu
    School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, Yale University, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, USA
    CNS Drugs 19:13-25. 2005
    ..The efficacy of this vaccine for relapse prevention is under investigation. Many initial promising findings need to be replicated in larger, controlled clinical trials...
  69. ncbi Pharmacologic management of relapse prevention in addictive disorders
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry, West Haven, CT, USA
    Psychiatr Clin North Am 27:627-48. 2004
    ..Further research is needed to develop new pharmacotherapies for substance use disorders and establish clinical guidelines on how to use these medications most effectively...
  70. ncbi Perfusion abnormalities and decision making in cocaine dependence
    Karen A Tucker
    Department of Psychiatry, Yale University School of Medicine, New Haven, USA
    Biol Psychiatry 56:527-30. 2004
    ..This study examined whether cocaine-dependent patients have perfusion abnormalities associated with poor decision-making ability as measured by the Iowa Gambling Task (IGT)...
  71. ncbi Consensus statement on office-based treatment of opioid dependence using buprenorphine
    David A Fiellin
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Subst Abuse Treat 27:153-9. 2004
    ....
  72. ncbi Effects of progesterone treatment on cocaine responses in male and female cocaine users
    Mehmet Sofuoglu
    Department of Psychiatry and VA Connecticut Healthcare System, School of Medicine, Yale University, West Haven, CT 06516, USA
    Pharmacol Biochem Behav 78:699-705. 2004
    ..The effects of progesterone treatment on cocaine dependence need to be further studied in controlled trials...
  73. ncbi Choosing a behavioral therapy platform for pharmacotherapy of substance users
    Kathleen M Carroll
    Department of Psychiatry, Yale University School of Medicine, VA CT Healthcare Center, 950 Campbell Avenue, West Haven, CT 06516, USA
    Drug Alcohol Depend 75:123-34. 2004
    ..Available manualized behavioral treatments are reviewed, noting their strengths and limitations as behavioral therapy platforms for pharmacotherapy trials and as potential concomitant therapies in clinical practice...
  74. ncbi Challenges in increasing access to buprenorphine treatment for opiate addiction
    Joyce C West
    Psychiatric Research Network, American Psychiatric Institute for Research and Education, 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209, USA
    Am J Addict 13:S8-16. 2004
    ..Increasing the understanding of specific financing and services delivery barriers that clinicians face is needed to inform the development of effective integrated services models and policies to facilitate OBOT implementation...
  75. ncbi Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure
    Alison Oliveto
    CT and VA Connecticut Healthcare System, Yale University, New Haven, 950 Campbell Avenue, Psychiatry 116A 4, Building 36, West Haven, CT 06516, USA
    Eur J Pharmacol 491:157-68. 2004
    ..These results suggest that isradipine attenuates and dextromethorphan enhances some of the behavioral effects of naloxone in opioid-dependent humans...
  76. ncbi Effects of smoking abstinence on visuospatial working memory function in schizophrenia
    Tony P George
    Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    Neuropsychopharmacology 26:75-85. 2002
    ..These results suggest that smoking abstinence differentially alters VSWM in schizophrenic vs. control smokers, and that cigarette smoking has beneficial effects on VSWM in schizophrenic, but not control, smokers...

Research Grants1

  1. Pharmacotherapy for opioid and cocaine dependence
    Bruce Rounsaville; Fiscal Year: 2005
    ..4. To examine depression as a predictor of response. 5. To examine three month follow-up status after completing the treatment trial for continuation in treatment, abstinence from illicit drugs, and depressive symptoms. ..